The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
Epicrispr raised $90M (Series C) to advance EPI-321, an epigenetic therapy that silences DUX4 in FSHD; early study enrollment complete. Epigenetic editing—controlling genes without altering DNA—proves safer alternative to genome editing, triggering pharma competition (Novartis, Sarepta, Arrowhead) and expanding genetic medicine addressable market.
An article from
Emerging biotech
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
Published Aug. 11, 2026
Epicrispr CEO Amber Salzman in the company lab.
Epicrispr secures $90M after early data on epigenetic FSHD treatment
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
Sarepta pushes back Elevidys timeline; Emergent lays off 90 staffers
CureC9 and BrainXell Partner to Advance ALS and FTD Research Through Patient-Driven Innovation
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - Scholar Rock Holdi
Greenstone Biosciences Receives NIH R61 Grant to Advance Cardiac Fibrosis Therapeutics for Duchenne Muscular Dystrophy
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
